Experts have warned that “medieval” levels of health inequality are severely straining Britain’s NHS, with the cost of treating illness linked to deprivation and poverty now estimated at £50 billion annually. This figure rivals the UK’s defence budget and reflects the hidden toll of rising child poverty and widespread hardship. Disturbing cases, including patients arriving at emergency departments with advanced, untreated cancers and an increase in self-harm for overnight shelter, highlight the extent of health neglect in the country’s most disadvantaged areas. Hospitals are also witnessing a rise in diseases reminiscent of the Victorian era, such as scabies, rickets, and scarlet fever. The findings are part of a detailed Guardian investigation into the growing impact of poverty on the UK’s overburdened health system. Senior NHS officials are calling the situation “chilling” and unsustainable, with growing fears that the system is being used as a last resort by those who have nowher

Many low-income Americans who rely on Medicaid due to chronic illnesses or disabilities are voicing deep concerns over a proposed medicaid work requirement included in President Trump’s “One Big Beautiful Bill Act.” The legislation aims to enforce that Medicaid recipients in 40 states and Washington, D.C., either work, volunteer, or attend school for at least 80 hours per month, or regularly prove exemption status through paperwork. For individuals like Stephanie Ivory of Columbus, Ohio, and Denise Sommer of Warrenton, Missouri, this proposal feels burdensome. Ivory, 58, suffers from gastrointestinal conditions and a bulging disc, rendering her unable to work. While she believes she’d qualify for an exemption, she worries about the difficulty of navigating additional reporting requirements. “It’s hard enough just renewing Medicaid every six months,” she said. Sommer, also 58, who has not worked in five years due to anxiety and arthritis, believes she could qualify with a doctor’s

Source: news.stv_.tv Health authorities in the UK have launched a formal investigation into the potential side effects of widely used Weight loss and diabetes medications following a surge in reports of pancreas-related complications Yellow Card Biobank . Nearly 400 patients have reported cases of acute pancreatitis—some of them fatal—after using GLP-1 (glucagon-like peptide-1 receptor agonists) drugs such as Mounjaro, Wegovy, Ozempic, and liraglutide. The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that over a quarter of these cases were reported in 2025 alone, with 101 incidents tied to tirzepatide (Mounjaro) and 22 to semaglutide (Ozempic and Wegovy). The agency emphasized that, although pancreatitis is listed as an “uncommon” side effect, the increasing usage of these injections has coincided with a rise in related health complaints submitted via the MHRA’s Yellow Card scheme. Acute pancreatitis, a sudden inflammation of the pancreas, can lead to sev

Diagnosed with Type 1 diabetes a decade ago, Smith had been managing the autoimmune condition with a demanding routine of insulin injections, diet monitoring, and blood sugar tracking.

A recent nationwide study conducted by Opera Beds places California among the top-performing states for lung health. The report, which assessed environmental and health-related data across all 50 U.S. states, found that California excels due to low smoking rates, cleaner air, and overall favorable environmental conditions. The Golden State ranked sixth overall in the final list of healthiest states for lungs. Researchers analyzed multiple variables contributing to chronic respiratory issues such as Chronic Obstructive Pulmonary Disease (COPD). These included smoking prevalence, air pollution levels, toxic chemical emissions, humidity, and COPD statistics from 2018 to 2023. To ensure accuracy, data was sourced from national organizations like the American Lung Association, the Environmental Protection Agency, and America’s Health Rankings. Due to missing recent data, Kentucky and Pennsylvania were not included in certain COPD-related comparisons.

The U.S. Food and Drug Administration (FDA) has officially approved lenacapavir, a groundbreaking drug for HIV Drug prevention, rooted in decades of research by University of Utah biochemist Wesley Sundquist. This medication, marketed under the name Yeztugo, was developed by Gilead Sciences and is already being hailed as a game-changer in the fight against HIV. Lenacapavir is designed to HIV Drug by targeting the virus’s protein shell—known as the capsid—essentially halting its ability to replicate. Sundquist’s laboratory laid the foundational understanding of this protein structure back in the late 1990s. His team discovered how sensitive the virus’s shell is to small changes, revealing a new path for treatment. Gilead Sciences took note of these findings and eventually collaborated with Sundquist to create lenacapavir. Unlike many existing HIV medications, lenacapavir stands out for its long-lasting protection. Administered just twice a year, it offers a six-month shield agains

Adenovirus can cause everything from pink eye to severe respiratory infections. Know the symptoms, how they spread, and how to protect your family. Read for more information

In a significant update to vaccination guidelines, federal health officials have redefined the eligibility criteria for receiving the respiratory syncytial virus (R.S.V.) vaccine eligibility